ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near Chicago, IL, USA:

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as...

Active, not recruiting
Non Small Cell Lung Cancer
Drug: NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel
Drug: NAI + Nivolumab + Ipilimumab

Phase 3

ImmunityBio
ImmunityBio

Tinley Park, Illinois, United States and 30 other locations

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Chicago, Illinois, United States and 83 other locations

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Chicago, Illinois, United States and 210 other locations

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently ...

Enrolling
Hepatocellular Cancer
Squamous-Cell Non-Small Cell Lung Cancer
Drug: ABBV-324
Drug: Lenvatinib

Phase 1

AbbVie
AbbVie

Chicago, Illinois, United States and 20 other locations

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study ...

Active, not recruiting
Stage IIIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Procedure: Surgery
Radiation: Radiotherapy

Phase 2

Alliance Foundation Trials

Chicago, Illinois, United States and 8 other locations

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

(pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung...

Enrolling
Carcinoma, Non-Small-Cell Lung (NSCLC)
Lung Cancer
Biological: Pembrolizumab
Biological: PF-08634404

Phase 3

Pfizer
Pfizer

New Lenox, Illinois, United States and 16 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Chicago, Illinois, United States and 123 other locations

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mort...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Carboplatin
Drug: Livmoniplimab

Phase 2, Phase 3

AbbVie
AbbVie

Chicago, Illinois, United States and 61 other locations

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Durvalumab
Procedure: Surgery

Phase 3

AstraZeneca
AstraZeneca

Chicago, Illinois, United States and 230 other locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...

Active, not recruiting
Metastatic Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Niles, Illinois, United States and 256 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems